A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer

A Study of QL1706 in Combination With Chemotherapy in PD-L1-Negative Non-small Cell Lung Cancer is a phase 3 interventional study registered as NCT05690945, led by Qilu Pharmaceutical, and active but no longer recruiting on the registry. Official title: A Randomised, Double-blind, Multicenter Phase 3 Clinical Study to Evaluate the Efficacy and Safety of QL1706 in Combination With Chemotherapy in First-line PD-L1 Negative, Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients. Planned enrolment is 606 participants (actual). The study started in 2023-02-15 and primary completion is expected in 2029-06. No results have been posted on ClinicalTrials.gov.